Loading…
← CockpitCompetitor Analysis › XFOR X4 Pharmaceuticals, Inc.Open in the cockpit ↗

X4 Pharmaceuticals, Inc.XFORCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum weak 27
Mkt cap
$304M
US dollars, full cap
Free float
76%
of shares outstanding
$/day
$2.50M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 7.1%
Hurdle
n/a
no reverse DCF
Next earnings
125 days
23 Mar 2027
Close · USD$2.98
1D-3.6%
1W-7.7%
1M-1.3%
3M-26.1%
6M-20.9%
YTD-25.5%
1Y-18.6%
ATR %8.5%
Beta1.62
52w lowhigh38.3% off high

What X4 Pharmaceuticals does

Employees: 45

X4 Pharmaceuticals at a glance

Size X4 Pharmaceuticals (XFOR) is a United States Health Care company (Biotechnology) with a market value of $304M, the 3070th largest of 3,085 United States companies the cockpit tracks. Shares closed at $2.98 on 18 Nov 2026.

Performance Over six months the shares fell 20.9%, against -31.0% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue fell 50.1% over the last twelve months (peer median +7.3%); the operating margin is -473.9% (peer median -115.0%).

Valuation It trades at 11.4× enterprise value to sales against a peer median of 5.3× (6th most expensive of 15).

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026XFOR 74Peer median 69
Six months, rebased to 100: X4 Pharmaceuticals against the median of its 20 peers (local-currency closes).

X4 Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$17.0M$35.1M$2.56M$0$0
Revenue growth—+1,273%———
Gross profit$13.7M$28.9M$1.46M-$2.00M-$1.99M
EBITDA-$78.5M-$85.6M-$141M-$106M-$86.1M
Net income-$80.5M-$79.2M-$37.5M-$101M-$93.9M
Free cash flown/a-$85.6M-$131M-$96.6M-$77.2M
Capital expenditure$5.00M$3.00M$7.33M$60,000$103,000
Total debt$77.2M$77.3M$78.1M$58.3M$38.4M

Quarterly statements and history in the cockpit →

X4 Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%-25%0%+25%1873GLSIGALT4894NAUTPROK76306945CCCC2105LRMR358570LYEL086900CRMDCTNM476060XFOR6-month return →1-month return →
Up and to the right = strong over both horizons. X4 Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×5,000×10,000×15,000×18734894PROK7630CCCC358570LYEL476060XFORRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. X4 Pharmaceuticals is the large dot.

X4 Pharmaceuticals competitors and peer comparison

How X4 Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

X4 Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureXFORPeer medianRank in peer set
1-month return-1.3%-5.7%6th highest of 20
6-month return-20.9%-31.0%8th highest of 20
Distance from 52-week high-38.3%-54.6%2nd highest of 20
Revenue growth (TTM)-50.1%+7.3%3rd lowest of 13
Operating margin-473.9%-115.0%6th lowest of 15
EV / Sales11.4×5.3×6th most expensive of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
X4 Pharmaceuticals XFORUnited States$304M-21%-50%-474%11.4×n/an/a
Viva Biotech 1873.HKHong Kong$303M-18%+7%10%1.0×2.6%+19.1%
Greenwich LifeSciences GLSIUnited States$302M-25%n/an/an/an/an/a
Galectin Therapeutics GALTUnited States$301M+35%n/an/an/an/an/a
Cuorips 4894.TJapan$309M-10%-80%-1,765%602.9×n/an/a
Nautilus Biotechnolgy NAUTUnited States$310M+2%n/a-15,106%588.9×n/an/a
ProKidney PROKUnited States$314M-38%+4%-24,830%1,625.4×n/an/a
IMPACT Therapeutics 7630.HKHong Kong$319M-79%+395%-173%9.5×n/an/a
AP Biosciences 6945.TWOTaiwan$321M-31%n/an/an/an/an/a
C4 Therapeutics CCCCUnited States$325M-25%+7%-316%5.4×n/an/a
Laekna 2105.HKHong Kong$326M-53%n/a-57%4.7×n/an/a
Medtide 3880.HKHong Kong$331M-17%+14%36%2.4×n/an/a
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%78.5×n/an/a
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%13,911.5×n/an/a
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%2.2×4.7%+11.9%
CorMedix CRMDUnited States$358M-43%+92%39%0.4×n/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%5.2×0.6%+725.2%
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%2.6×n/an/a

Questions

Which companies are X4 Pharmaceuticals's closest peers?
The cockpit's peer set: Viva Biotech (1873.HK), Greenwich LifeSciences (GLSI), Galectin Therapeutics (GALT), Cuorips (4894.T), Nautilus Biotechnolgy (NAUT), ProKidney (PROK), IMPACT Therapeutics (7630.HK), AP Biosciences (6945.TWO).
Is X4 Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 11.4× against a peer median of 5.3×, 6th most expensive of 15 in its peer set.
How has X4 Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -20.9% against -31.0% for the median peer; over one year -18.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.